MYOK News and Press, MyoKardia Inc. From 08/11/20

Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation:  MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos Gianakakos, MyoKardia’s CEO, to Join LianBio Board of Directors BRISBANE, ...

BRISBANE, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial during a late-breaker session at the upcoming European Society of Cardiology Congress 2020 (ESC ...

BRISBANE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 3:30 p.m. ET. A webcast of the presentation wi...

Image source: The Motley Fool. MyoKardia, Inc.   (NASDAQ: MYOK) Q2 2020 Earnings Call Aug 4, 2020 , 4:30 p.m. ET Operator Continue reading

MyoKardia, Inc. (MYOK) Q2 2020 Earnings Conference Call August 04, 2020, 16:30 ET Company Participants Tassos Gianakakos - President, CEO & Director Jay Edelberg - SVP, Clinical Development William Fairey - Chief Commercial Officer & EVP Taylor Harris - CFO Conferenc...

MyoKardia (NASDAQ: MYOK ) : Q2 GAAP EPS of -$1.27 beats by $0.18 . More news on: MyoKardia, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BRISBANE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020. “The second quarter of 2020 was one of incredible progress across our R&D pipeline, including the exciting new data ...

MyoKardia reports initiating trial for invasive septal reduction therapy MyoKardia Inc. ( MYOK ) announced that it has dosed the first person for the Phase 3 VALOR-HCM clinical trial. The study aims to provide direct clinical evidence of mavacamten’s capability to alleviate the re...

BRISBANE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, August 3rd by MyoKardia, Inc. (Nasdaq: MYOK), please note that the second quote by Jeffrey B. Geske, M.D. has changed. The corrected release follows: MyoKardia, Inc. (Nasdaq: MY...

The first patient has been dose d in a Phase 3 clinical, VALOR-HCM , evaluating MyoKardia's ( MYOK -0.5% ) mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) who have been referred for septal reduction therapy (SRT) and are refractory to current therapeutic options...